Diverse amide analogs of sulindac for cancer treatment and prevention

Academic Article

Abstract

  • Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has shown significant anticancer activity. Sulindac sulfide amide (1) possessing greatly reduced COX-related inhibition relative to sulindac displayed in vivo antitumor activity that was comparable to sulindac in a human colon tumor xenograft model. Inspired by these observations, a panel of diverse sulindac amide derivatives have been synthesized and their activity probed against three cancer cell lines (prostate, colon and breast). A neutral analog, compound 79 was identified with comparable potency relative to lead 1 and activity against a panel of lymphoblastic leukemia cell lines. Several new series also show good activity relative to the parent (1), including five analogs that also possess nanomolar inhibitory potencies against acute lymphoblastic leukemia cells. Several new analogs identified may serve as anticancer lead candidates for further development.
  • Digital Object Identifier (doi)

    Author List

  • Mathew B; Hobrath JV; Connelly MC; Kiplin Guy R; Reynolds RC
  • Start Page

  • 4614
  • End Page

  • 4621
  • Volume

  • 27
  • Issue

  • 20